You are here

  • Home
  • Archive
  • Volume 72, Issue 2
  • Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic

Article info

Article menu
COVID-19
Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic
Free

Authors

  • Nicholas A Kennedy Department of Gastroenterology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, Exeter, UK PubMed articlesGoogle scholar articles
  • Malik Janjua Department of Gastroenterology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, Exeter, UK PubMed articlesGoogle scholar articles
  • Neil Chanchlani Department of Gastroenterology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, Exeter, UK PubMed articlesGoogle scholar articles
  • Simeng Lin Department of Gastroenterology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, Exeter, UK PubMed articlesGoogle scholar articles
  • Claire Bewshea Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, Exeter, UK PubMed articlesGoogle scholar articles
  • Rachel Nice Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, Exeter, UK Department of Biochemistry, Exeter Clinical Laboratory International, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK PubMed articlesGoogle scholar articles
  • Timothy J McDonald Department of Biochemistry, Exeter Clinical Laboratory International, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK PubMed articlesGoogle scholar articles
  • Cressida Auckland Department of Microbiology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK PubMed articlesGoogle scholar articles
  • Lorna W Harries Institute of Biomedical and Clinical Sciences, University of Exeter, Exeter, UK PubMed articlesGoogle scholar articles
  • Merlin Davies Institute of Biomedical and Clinical Sciences, University of Exeter, Exeter, UK PubMed articlesGoogle scholar articles
  • Stephen Michell College of Life and Environmental Sciences, University of Exeter, Exeter, UK PubMed articlesGoogle scholar articles
  • Klaartje B Kok Centre for Immunobiology, Blizard Institute, Barts and the London School of Medicine, Queen Mary University of London, London, UK Department of Gastroenterology, Royal London Hospital, Barts Health NHS Trust, The Royal London Hospital, London, UK PubMed articlesGoogle scholar articles
  • Christopher A Lamb Department of Gastroenterology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK Translational & Clinical Research Institute, Newcastle University Faculty of Medical Sciences, Newcastle upon Tyne, UK PubMed articlesGoogle scholar articles
  • Philip J Smith Department of Gastroenterology, Royal Liverpool Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK PubMed articlesGoogle scholar articles
  • Ailsa L Hart Department of Gastroenterology, St Mark's Hospital and Academic Institute, London, UK PubMed articlesGoogle scholar articles
  • Richard CG Pollok Department of Gastroenterology, St George's University Hospitals NHS Foundation Trust, London, UK Institute for Infection & Immunity, St George's University of London, London, UK PubMed articlesGoogle scholar articles
  • Charlie W Lees Department of Gastroenterology, Western General Hospital, Edinburgh, UK Institute of Genetic and Molecular Medicine, University of Edinburgh Western General Hospital, Edinburgh, UK PubMed articlesGoogle scholar articles
  • Rosemary J Boyton Department of Infectious Disease, Imperial College London, London, UK Lung Division, Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, UK PubMed articlesGoogle scholar articles
  • Daniel M Altmann Department of Immunology and Inflammation, Imperial College London, London, UK PubMed articlesGoogle scholar articles
  • Shaji Sebastian IBD Unit, Department of Gastroenterology, Hull University Teaching Hospitals NHS Trust, Hull, UK Hull York Medical School, University of Hull, Hull, UK PubMed articlesGoogle scholar articles
  • Nicholas Powell Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK Department of Gastroenterology, Imperial College Healthcare NHS Trust, London, UK PubMed articlesGoogle scholar articles
  • James R Goodhand Department of Gastroenterology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, Exeter, UK PubMed articlesGoogle scholar articles
  • Tariq Ahmad Department of Gastroenterology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, Exeter, UK PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Tariq Ahmad, Department of Gastroenterology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK; tariq.ahmad1{at}nhs.net
View Full Text

Citation

Kennedy NA, Janjua M, Chanchlani N, et al
Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic
Gut 2023;72:295-305.

Publication history

  • Received April 8, 2022
  • Accepted July 16, 2022
  • First published July 28, 2022.
Online issue publication 
May 11, 2023

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for personal use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage